Moving forward in advanced bladder cancer

Journal of Clinical Oncology

Volumn 25, Issue 16, 2007, Pages 2162-2163

  Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; VINBLASTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; M VAC PROTOCOL; M-VAC PROTOCOL; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADVANCED CANCER; BLADDER CANCER; BONE METASTASIS; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; EDITORIAL; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LIVER METASTASIS; METASTASIS; MORTALITY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; BLADDER TUMOR; CHEMISTRY; DRUG ANTAGONISM; NOTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; HUMANS; METHOTREXATE; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 34250218604     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3630     Document Type: Editorial

References (15)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
3. Von der Masse H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multiinstitutional, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
4. Sternberg CN, de Mulder PHM, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for the Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 19:2638-2646, 2001
5. Hussain MHA, MacVicar GR, Petrylak DP, et al: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218-2224, 2007
6. Jimenez RE, Hussain M, Bianco FJ Jr, et al: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447, 2001
7. Hussain M, Vaishampayan U, Du W, et al: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial carcinoma. J Clin Oncol 19:2527-2533, 2001
8. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3183, 1999
9. Bellmunt J, Ribas A, Eres N, et al: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997
10. Petriolo R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77:344-351, 1996
11. Bellrnunt J, Guillem V, Paz-Ares L, et al: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium: Spanish Oncology Genitourinary Group. J Clin Oncol 18:3247-3255, 2000
12. Bajorin DF, McCaffrey JA, Dodd PM, et al: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 88:1671-1678, 2000
13. Nguyen PL, Swanson PE, Jaszcz W, et al: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: A multivariate survival analysis. Am J Clin Pathol 101:166-176, 1994
14. Petrylak D, Faulkner JR, Van Veldhuizen PJ, et al: Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group trial. Proc Am Soc Clin Oncol 22:403, 2003 (abstr 1619)
15. Philips G, Sanford B, Halabi S, et al: Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102. J Clin Oncol 24:236s, 2006 (suppl; abstr 4578)